The role of preoperative chemotherapy for colorectal cancer metastases in the liver with the lack of RAS mutations
- Authors: Lazarev A.F1, Mamontov K.G1, Kotelnikov A.G1, Khays S.L.1, Lubennikov V.A1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center
- Issue: Vol 21, No 5 (2016)
- Pages: 238-243
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40297
- DOI: https://doi.org/10.18821/1028-9984-2016-21-5-238-243
- ID: 40297
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
A. F Lazarev
N.N. Blokhin Russian Cancer Research CenterAltai Branch Barnaul, 656049, Russian Federation
K. G Mamontov
N.N. Blokhin Russian Cancer Research CenterAltai Branch Barnaul, 656049, Russian Federation
A. G Kotelnikov
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
Sergey L. Khays
N.N. Blokhin Russian Cancer Research Center
Email: khayss@mail.ru
MD, senior researcher of the Department of the Surgery of Liver and Pancreas Barnaul, 656049, Russian Federation
V. A Lubennikov
N.N. Blokhin Russian Cancer Research CenterAltai Branch Barnaul, 656049, Russian Federation
References
- WHO, IARC GLOBOCAN. Cancer Incidence and Mortality Worldwide 2008 http://globocaniarc.fr
- Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Злокачественные новообразования в России в 2013 году. М.: Издательство МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России; 2013.
- Goldberg R.M., Sargent D.J., Morton R.F. et al. A randomized controlled trial of fluorouracil plus’leucovorin, irinotecan, and oxaliplatin com-binations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2004; 22 (1): 23-30.
- Hurwitz H., Fehrenbacher L., Novotny W. et al. Bevacizumab plus irinotecan. fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004 3; 350(23): 2335-42.
- Falcone A., Ricci S., Brunetti I. et al. Phase III trial of infusionalfluo-rouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the GruppoOncologicoNordOvest. J. Clin. Oncol. 2007; 25 (13): 1670-6.
- Saltz L.B., Clarke S., Diaz-Rubio E. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 2008; 26 (12): 2013-9.
- Bokemeyer C., Bondarenko I., Hartmann I.T. et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as firsf-line treatment for metastatic colorectal cancer: the OPUS study. Ann. Oncol. 2011; 22 (7): 1535-46.
- Van Cutsem E. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 2011; 29 (15): 2011-9.
- Douillard J.Y. Final results from PRIME: randomized phase III study of panitumumab with FOIF0X4 for first-line treatment of metastatic colorectal cancer. Ann. Oncol. 2014; 25 (7): 1346-55.
- Heinemann V., von Weikersthal L.F., Decker T. et al. FOLFIRI plus cetux-imab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label,phase 3 trial. Lancet Oncol. 2014; 15: 1065-75.
- Stintzing S., Jung A., Rossius L., Modest D.P., L. Fischer von Weikersthal, Decker T. et al. Analysis ofKRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study ofFOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. In: 2013 European Cancer Congress. 2013: Abstr. 17.
- Schwartzberg L.S., Rivera F, Karthaus M. et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracilleucovorin, and oxaliplatin (mFOLFOx6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J. Clin. Oncol. 2014; 32: 2240-7.
- Peeters M. et al. Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (inCRC). J. Clin. Oncol. 2014; 32 (Suppl. 3): Abstr. LBA387.
- Adams R.A., Meade A.M., Seymour M.T. et al. Intermittenvs continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomized phase 3 MRC COIN trial. Lancet Oncol. 2011; 12 (7): 642-53.
- Maughan T.S., Adams R.A., Smith C.G. et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of randomized phase 3 MRC COIN trial. Lancet. 2011; 377 (9783): 2103-14.
- Tveit K., Guren T., Glimelius B. et al. Randomized phase III study of 5-flurouracil/folinate/oxaliplatin given continuously or intermittently with or without of cetuximab, as first-line therapy of metastatic colorectal cancer: the NORDIC VII study (NCT0014314), by the Nordic Colorectal Cancer Biomodulation Group. J. Clin. Oncol. 2011; 29 (Suppl. 4): Abstr. 365.
- Tabernero J., Pfeiffer P., Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist. 2008; 13(2): 113-9. doi: 10.1634/theoncologist.2007-0201.
- Lièvre A., Bachet J.B., Boige V., Cayre A., Le Corre D., Buc E. et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 2008; 26(3): 374-9.
- Bokemeyer C., Bondarenko I., Makhson A., Hartmann J.T., Aparicio J., de Braud F. et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2009; 27(5): 663-71.
- Rougier P., Mitry E. Targeted biotherapy: a revolution in the management of patients with colorectal cancer? Gastroenterol. Clin. Biol. 2009; 33(8-9): 672-80.